Delivery Order SPE2DB24D9222-SPE2DB25FAZBG
Award Date
10/22/24
Potential Completion Date
11/13/24
Potential Value
$15K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $9,671.25 firm fixed-price delivery order is for the pharmaceutical product XOLAIR 150 MG/ML SYRINGEML, with a completion date of June 4, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue delivery...
This is a federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $15,474.00 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product. The award is not associated with any set-aside designation. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order valued at $7,737.00 for the supply of Xolair 150 mg/ml syringes. The award was made by the Defense Logistics Agency (DLA) under the Medical Supply Chain program, which facilitates the distribution of pharmaceutical products and medical supplies to Department of Defense (DoD) healthcare facilities worldwide. The contract has no set-aside designation and is part of a...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $7,737.00 for the supply of XOLAIR 150 MG/ML SYRINGEML to the Defense Logistics Agency (DLA), which is the primary logistics and supply agency for the U.S. Department of Defense. The contract has an ultimate completion date of March 4, 2025 and is a firm fixed-price delivery order, with no set-aside designation. DMS Pharmaceutical Group Inc. holds...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order worth $3,868.50 for the provision of Xolair 150 mg/mL syringes. The contract is a firm fixed-price award with no set-aside designation, awarded by the Defense Logistics Agency (DLA) under the Medical Supply Chain program. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA, which allows the agency to issue delivery orders for a wide...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order valued at $15,474.00 for the pharmaceutical product Xolair 150 mg/ml syringe. The contract is a firm fixed-price award issued by the Defense Logistics Agency (DLA), a defense agency, and does not have a set-aside designation. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a range of branded and generic prescription drugs,...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $9,284.40 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a pharmaceutical product, with an ultimate completion date of October 25, 2024. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, which allows the agency to...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense (DoD). The $4,642.20 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialty pharmaceutical product, to fulfill the recurring medical supply needs of military health facilities. The award is not associated with any set-aside program. DMS Pharmaceutical Group holds a...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order valued at $98,132.40 issued by the Defense Logistics Agency (DLA) under the SPE2DB Indefinite Delivery Contract (IDC). The contract is for the delivery of XOLAIR 150 MG/ML SYRINGEML, a specialized pharmaceutical product. The IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical items to support the medical supply needs...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order (SPE2DB24FL0H6) under the Defense Logistics Agency's (DLA) SPE2DB program. The $9,284.40 award is for the supply of XOLAIR 75 MG/0.5 ML SYRINGE 0.5ML, a pharmaceutical product, to fulfill the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group is an established federal contractor that provides a comprehensive range of pharmaceutical...